PH12017501927B1 - Methods of polynucleotide preparation using multivalent cation salt compositions - Google Patents

Methods of polynucleotide preparation using multivalent cation salt compositions

Info

Publication number
PH12017501927B1
PH12017501927B1 PH1/2017/501927A PH12017501927A PH12017501927B1 PH 12017501927 B1 PH12017501927 B1 PH 12017501927B1 PH 12017501927 A PH12017501927 A PH 12017501927A PH 12017501927 B1 PH12017501927 B1 PH 12017501927B1
Authority
PH
Philippines
Prior art keywords
polynucleotide
salt
multivalent cation
methods
cation salt
Prior art date
Application number
PH1/2017/501927A
Other languages
English (en)
Other versions
PH12017501927A1 (en
Inventor
Premchandran H Ramiya
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of PH12017501927A1 publication Critical patent/PH12017501927A1/en
Publication of PH12017501927B1 publication Critical patent/PH12017501927B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • C12N2310/3145Phosphoramidates with the nitrogen in 3' or 5'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2017/501927A 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions PH12017501927B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23
PCT/US2016/028657 WO2016172346A1 (en) 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions

Publications (2)

Publication Number Publication Date
PH12017501927A1 PH12017501927A1 (en) 2018-03-05
PH12017501927B1 true PH12017501927B1 (en) 2022-09-02

Family

ID=55911083

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2017/501927A PH12017501927B1 (en) 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions

Country Status (36)

Country Link
US (2) US10745687B2 (enExample)
EP (1) EP3286203B1 (enExample)
JP (4) JP2018513127A (enExample)
KR (1) KR102401252B1 (enExample)
CN (2) CN107429247B (enExample)
AU (2) AU2016250576C1 (enExample)
BR (1) BR112017019627B1 (enExample)
CA (1) CA2978191C (enExample)
CL (1) CL2017002314A1 (enExample)
CO (1) CO2017009217A2 (enExample)
CY (1) CY1123197T1 (enExample)
DK (1) DK3286203T3 (enExample)
EA (1) EA035885B1 (enExample)
ES (1) ES2798270T3 (enExample)
HR (1) HRP20201218T1 (enExample)
HU (1) HUE051148T2 (enExample)
IL (1) IL254222A0 (enExample)
LT (1) LT3286203T (enExample)
MA (2) MA42569B1 (enExample)
MD (1) MD3286203T2 (enExample)
ME (1) ME03811B (enExample)
MX (1) MX383293B (enExample)
MY (1) MY187804A (enExample)
PE (2) PE20221275A1 (enExample)
PH (1) PH12017501927B1 (enExample)
PT (1) PT3286203T (enExample)
RS (1) RS60645B1 (enExample)
SA (1) SA517390103B1 (enExample)
SG (2) SG11201707893RA (enExample)
SI (1) SI3286203T1 (enExample)
SM (1) SMT202000389T1 (enExample)
TN (1) TN2017000411A1 (enExample)
TW (1) TWI736532B (enExample)
UA (1) UA124521C2 (enExample)
WO (1) WO2016172346A1 (enExample)
ZA (1) ZA201706041B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP4060345A1 (en) 2016-12-19 2022-09-21 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
US11866696B2 (en) * 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
JP7441455B2 (ja) * 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド
EP3727470B1 (en) 2017-12-18 2024-11-20 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69130333T2 (de) 1990-08-31 1999-03-04 Regents Of The University Of Minnesota, Minneapolis, Minn. Harze für die Feststoff-Peptidsynthese
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
PL316434A1 (en) 1994-03-18 1997-01-06 Lynx Therapeutics Oligonucleotidic phosphoramides n3'-p5', their compositions, synthesising and hydridising methods as well as immunological properties in respect to nuclease
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
JP2002060341A (ja) 2000-08-21 2002-02-26 Terumo Corp 止血剤
WO2002077184A2 (en) 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
CN101321877B (zh) * 2005-10-03 2013-04-10 应用生物系统有限责任公司 用于扩增核酸的组合物、方法和试剂盒
WO2008127305A2 (en) 2006-11-01 2008-10-23 Biogen Idec Ma Inc. Method of isolating biomacromolecules using low ph and divalent cations
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
ES2770638T3 (es) * 2012-06-14 2020-07-02 Life Technologies Corp Nuevas composiciones, métodos y kits para la reacción en cadena de la polimerasa (PCR)
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Also Published As

Publication number Publication date
TW201706284A (zh) 2017-02-16
EA201791753A1 (ru) 2018-04-30
CA2978191C (en) 2022-10-04
TWI736532B (zh) 2021-08-21
HUE051148T2 (hu) 2021-03-01
CL2017002314A1 (es) 2018-05-04
SG10201909816PA (en) 2019-11-28
JP2025061848A (ja) 2025-04-11
US20200339975A1 (en) 2020-10-29
BR112017019627A2 (pt) 2018-05-15
AU2016250576B2 (en) 2021-02-04
UA124521C2 (uk) 2021-10-05
SA517390103B1 (ar) 2021-07-14
AU2016250576A1 (en) 2017-09-21
KR102401252B1 (ko) 2022-05-24
AU2021202803A1 (en) 2021-06-03
CY1123197T1 (el) 2021-10-29
RS60645B1 (sr) 2020-09-30
CO2017009217A2 (es) 2018-02-20
PT3286203T (pt) 2020-07-08
ZA201706041B (en) 2020-11-25
BR112017019627B1 (pt) 2022-11-29
JP2021152079A (ja) 2021-09-30
CN113564168A (zh) 2021-10-29
AU2016250576C1 (en) 2021-05-06
NZ735042A (en) 2021-11-26
PH12017501927A1 (en) 2018-03-05
PE20171785A1 (es) 2017-12-27
CN107429247A (zh) 2017-12-01
SI3286203T1 (sl) 2020-10-30
WO2016172346A1 (en) 2016-10-27
IL254222A0 (en) 2017-10-31
MD3286203T2 (ro) 2020-08-31
MX383293B (es) 2025-03-13
PE20221275A1 (es) 2022-09-01
CN113564168B (zh) 2024-10-25
US11441144B2 (en) 2022-09-13
HK1251234A1 (en) 2019-01-25
KR20170138399A (ko) 2017-12-15
MY187804A (en) 2021-10-26
US10745687B2 (en) 2020-08-18
TN2017000411A1 (en) 2019-01-16
MA42157A (fr) 2018-02-28
SMT202000389T1 (it) 2020-09-10
SG11201707893RA (en) 2017-11-29
JP2018513127A (ja) 2018-05-24
EP3286203B1 (en) 2020-05-06
ES2798270T3 (es) 2020-12-10
EP3286203A1 (en) 2018-02-28
DK3286203T3 (da) 2020-06-02
HRP20201218T1 (hr) 2020-12-11
LT3286203T (lt) 2020-07-27
JP2022168017A (ja) 2022-11-04
EA035885B1 (ru) 2020-08-27
US20160312227A1 (en) 2016-10-27
MA42569B1 (fr) 2020-08-31
MX2017011642A (es) 2017-11-02
ME03811B (me) 2021-04-20
CA2978191A1 (en) 2016-10-27
CN107429247B (zh) 2021-08-13

Similar Documents

Publication Publication Date Title
PH12017501927A1 (en) Methods of polynucleotide preparation using multivalent cation salt compositions
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BR112018006562A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, conjugado e uso de um anticorpo
BR112017003582A2 (pt) anticorpos, composições e usos
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
EA201400483A1 (ru) Составы собирателей и способы их применения
BR112017003784A2 (pt) ferramentas de produtividade para autorização de conteúdo
MX390920B (es) Moléculas de unión a lag-3 y métodos de uso de las mismas.
EA201791093A1 (ru) Антитела к cd47, способы и применение
MX386491B (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
MX2022011281A (es) Npp1 para usarse en el tratamiento de calcificacion de tejidos.
BR112017023131A2 (pt) anticorpos anti- fcrn
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
BR112016030950A2 (pt) polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
BR112018005464A2 (pt) expressão de proteínas contendo fc
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MY191596A (en) Igf-1r antibody and its use for the diagnosis of cancer
BR112014012997A2 (pt) ligantes que se ligam à opsina, composições e métodos de uso
Fleming et al. Looking forward: Preparing Yukon teachers for Yukon schools: Review of the Yukon native teacher education program at Yukon College, 2011-2012